Estrogen receptor and androgen receptor imaging in metastatic breast cancer patients

niversity Medical Center Groningen0 个研究点开始时间: 2013年11月22日最近更新: 2016年10月3日

试验速览

暂无简介。

•1. Metastatic breast cancer, with at least one known metastasis outside of the liver
•2. Presence of a lesion that is safely accessible for tumor biopsy (may be liver lesion)
•3. Postmenopausal status defined as one of the following:
•a. age =60 years
•b. previous bilateral oophorectomy
•c. age <60 years and amenorrhea for >12 months in the absence of interfering hormonal therapies (such as LH-RH agonists and ER-antagonists)
•d. patients age <60 years using an ER-antagonist should have amenorrhea for > 12 months and FSH >24 U/L and LH >14 U/L
•e. patient age <60 years using LH-RH agonists should continue LH-RH-agonists until after the PET procedures
•4. Initially ER-positive tumor histology.
•5. ECOG performance status 0-2.
•6. Signed written informed consent
•7. Able to comply with the protocol
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•1. Use of estrogen receptor ligands, including tamoxifen, fulvestrant or estrogens, or androgen receptor ligands, during the 6 weeks before entry into the study
•2. Life-expectancy = 3 months

发起方